Amphivena Therapeutics lands $62 mln Series C
South San Francisco-based Amphivena Therapeutics Inc, a developer of T cell engager therapeutics for cancer, has raised $62 million in Series C financing. NanoDimension and Qiming Venture Partners USA led the round.
24 September 2019•1 min read
